Technology/ Title:PDC-TacroBCR®

Technology Type:
Pharmaceutical

Contact Person

Name:
Chih-Chiang Yang
Title:
Director
Telephone(work):
+886-66251166 ext. 7501
Mobile:
0972232293

Technology Description

Biphasic controlled release formulation of tacrolimus provide better therapeutic effect on drug onset and maintenance in plasma concentration for daily use. This product will aid patients to improve life quality for prophylaxis of organ rejection cases.

Intellectual Property

Patents:

Preparing for filing

Key Publications:

Business Opportunity

Tacrolimus is the main anti-rejection drug after organ transplantation. However, due to its low solubility and poor absorption, there is also a high blood drug concentration leading to neurotoxic side effects, resulting in poor patient compliance. PDC-TacroBCR® will aid patients to improve life quality for prophylaxis of organ rejection cases.